[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-renal-cell-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-renal-cell-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634482","caix-pet-ct-guided-radiation-therapy-in-ccrcc-100634482",false,"NCT07540260","CAIX PET\u002F CT Guided Radiation Therapy in CcRCC.","COSTAR-002","Inclusion Criteria:\n\nAdults (≥18 years) Histologically confirmed clear cell renal cell carcinoma Recurrent or metastatic disease Planned or ongoing first-line systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) Dual PET\u002FCT imaging available (FDG PET\u002FCT and CAIX-targeted PET\u002FCT) and eligible for radiotherapy planning Multidisciplinary assessment confirms radiotherapy is feasible to treat ≥75% of detectable lesions Able to provide written informed consent\n\nExclusion Criteria:\n\nUnable to receive stereotactic radiotherapy as planned Uncontrolled serious comorbidities or active infection Pregnant or breastfeeding Unable or unwilling to comply with study procedures and follow-up","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET\u002FCT imaging (FDG PET\u002FCT and a CAIX-targeted PET\u002FCT) to map disease sites. When feasible, PET\u002FCT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \\~70).",[26,27,28],"Radiation Therapy","Metastatic Renal Cancer","Recurrent Renal Cell Cancer",[30,27,28],"SBRT","RECRUITING","2026-04-13",{"date":34,"type":35},"2026-04-20","ACTUAL",{"date":37,"type":35},"2025-11-01",{"date":39,"type":20},"2030-12-31",{"name":41,"class":42},"Peking University First Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100560893","sabr-combined-with-targeted-therapy-and-anti-pd-1-for-recurrent-or-metastatic-renal-cancer-100560893","NCT06583070","SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer","Cohort Study of SABR Combined With Targeted Therapy and Anti-PD-1 Versus Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cell Carcinoma Patients","COSTAR","Inclusion Criteria:\n\n* Patients with histologically confirmed renal cancer; diagnosed with recurrent or metastatic renal cancer via PET\u002FCT or other whole-body imaging.\n* Evaluated by the radiation oncology and imaging departments as having at least one lesion amenable to radiation therapy.\n* Planning to undergo or currently receiving first-line or second-line targeted therapy combined with immunotherapy.\n* Voluntarily agrees to participate in the study and signs an informed consent form.\n* Male or female, aged ≥18 years (inclusive).\n* Expected survival of ≥12 weeks.\n* At least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* European Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate cardiac, bone marrow, liver, and renal function.\n* Willing and able to comply with the study procedures and follow-up schedule.\n\nExclusion Criteria:\n\n* Extensive, multiple metastases;\n* Presence of central nervous system metastases and\u002For carcinomatous meningitis.\n* Toxicity from previous treatments not yet recovered to grade 0-1 (excluding grade 2 alopecia);\n* Other severe, uncontrollable co-morbid conditions that could affect protocol compliance or confound interpretation of results, including active opportunistic or severe progressive infections, uncontrolled diabetes, uncontrolled hypertension, cardiovascular diseases (defined as New York Heart Association Class III or IV heart failure, second-degree or higher heart block, myocardial infarction within the last 12 months, unstable arrhythmias or angina, stroke within the last 6 months), or pulmonary diseases (interstitial pneumonia, obstructive pulmonary disease, and symptomatic bronchospasm history), deep vein thrombosis or pulmonary embolism within the last 6 months;\n* Diagnosed with other malignancies within 5 years prior to enrollment, except:\n* Localized low-risk prostate cancer (defined as stage ≤T2b, Gleason score ≤7, and PSA ≤20ng\u002FmL at diagnosis, who have undergone curative treatment with no recurrence of prostate-specific antigen);\n* Malignancies treated with a curative intent that are considered cured, including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with surgery;\n* Pregnant or breastfeeding women;\n* Positive HIV test result;\n* Active hepatitis B or C infection;\n* Active tuberculosis;\n* Any other conditions, metabolic abnormalities, physical examination or laboratory findings that in the investigator's judgment might indicate an unsuitability for the study drug, could interfere with the interpretation of study results, or place the patient at high risk if they participate in the study;\n* Estimated insufficient compliance with the clinical study.","MALE","85 Years",{"count":55,"type":20},300,"OBSERVATIONAL","Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area, with Peking University First Hospital treating over 1,000 kidney cancer patients annually. Once recurrence or metastasis occurs, the prognosis is poor, with median progression times of 1-2 years after first-line systemic therapy (targeted therapy combined with immunotherapy). Enhancing local control of lesions is key to improving overall survival. Combining local radiotherapy with systemic treatment may be one approach to address this issue. Currently, Stereotactic Ablative Radiotherapy (SABR) enables precise tumor ablation and can activate the body's immune response. Studies show that the one-year local control rate after SABR exceeds 90%. Preliminary research by the applicant has shown that the combination of drug therapy and SABR for recurrent metastatic renal cancer can extend progression-free survival beyond two years, with earlier intervention leading to more significant survival improvements. This study aims to evaluate the efficacy and safety of combining SABR with targeted and immunotherapy for recurrent metastatic renal cancer through a multicenter, bidirectional cohort design, exploring new therapeutic strategies.",[26,27,28],[30,27,28],"2026-01-27",{"date":62,"type":35},"2026-01-28",{"date":64,"type":35},"2024-02-02",{"date":66,"type":20},"2027-03-31",{"name":41,"class":42},2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100522862","contrast-enhanced-ct-based-deep-learning-model-for-preoperative-prediction-of-disease-free-survival-dfs-in-localized-clear-cell-renal-cell-carcinoma-ccrcc-100522862","NCT06088134","Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)","Urology Department of the First Affiliated Hospital of Chongqing Medical University","Inclusion Criteria:\n\n* underwent partial\u002Fradical nephrectomies\n* histologically diagnosed as ccRCC\n* with complete clinical data and preoperative CT image data\n\nExclusion Criteria:\n\n* with incomplete clinic-pathological data\n* lack of preoperative contrast-enhanced CT images or the image quality was unsuitable for analysis\n* who received pre-surgery neoadjuvant or adjuvant therapies\n* with multiple renal tumors or\u002Fand had synchronous metastasis",{"count":77,"type":20},800,"This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's predictive ability with traditional models.",[80,81,28],"Clear Cell Renal Cell Carcinoma","Prognostic Cancer Model","2025-05-27",{"date":84,"type":35},"2025-05-31",{"date":86,"type":35},"2022-09-01",{"date":88,"type":20},"2025-08-01",{"name":90,"class":42},"Mingzhao Xiao"]